← Back to Search

Quitbot Program for Smoking Cessation

Phase 3

Waitlist Available

Led By Jonathan B. Bricker

Research Sponsored by Fred Hutchinson Cancer Research Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 or older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 3 and 6 months after randomization

Awards & highlights

No Placebo-Only Group

Pivotal Trial

Summary

This trial is comparing two different ways to help people quit smoking cigarettes.

Who is the study for?

This trial is for smokers who have smoked at least one cigarette daily for the past year, want to quit within a month, and are willing to try a digital program. They must live in the US, read English, not use other cessation methods, be open to random assignment to either program, and have daily access to a smartphone with text messaging and Facebook Messenger.

What is being tested?

The study compares two remote digital smoking cessation programs. Participants will receive support through their smartphones using either an experimental or control program designed to help them stop smoking.

What are the potential side effects?

Since this trial involves non-medical interventions (digital programs), traditional side effects like those from drugs aren't expected. However, participants may experience stress or frustration related to quitting smoking.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 3 and 6 months after randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 3 and 6 months after randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 3 and 6 months after randomization for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Number of participants with 30-day biochemically confirmed cigarette smoking cessation

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Pivotal Trial

The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group I (QuitBot Experimental)Experimental Treatment1 Intervention

Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.

Group II: Group II (QuitBot Control)Active Control1 Intervention

Participants participate in the Quitbot program for 42 days to support quitting smoking. Therapy description withheld to protect the integrity of the study.

0 / 1Eligibility criteria met